Since the manipulation of these miRNAs has been shown to affect whole-body energy expenditure, glucose tolerance and insulin sensitivity in vivo, they represent potentially critical therapeutic targets for treating obesity and related metabolic complications. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.